Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism-based drug repurposing in HFpEF (REPO-HFPEF)
2022-003111-28Phase 2Completed
- Sponsor
- Hospital Clínico Universitario de Valencia
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of vericiguat, citrulline and folate in heart failure with preserved ejection fraction (HFpEF), sponsored by Hospital Clínico Universitario de Valencia. Primary endpoint: Safety profile (all adverse drug reactions). Started Nov 2022; status: completed.
02
Drugs
vericiguatcitrullinefolate
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2022-003111-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003111-28.